

## **DEVELOPMENT AND VALIDATION OF A PROPRIETARY MEDIUM FORMULATION FOR RECOMBINANT SUBUNIT VACCINES BY THE BACULOVIRUS EXPRESSION VECTOR SYSTEM (BEVS)**

Catherine Cleuziat, Boehringer-Ingelheim, France  
catherine.cleuziat@boehringer-ingelheim.com  
Sophie Biard, Boehringer-Ingelheim, France  
Géraldine Popovic, Boehringer-Ingelheim, France  
Sylvain Lagresle, Boehringer-Ingelheim, France  
Chloé Damiany, Boehringer-Ingelheim, France  
Christine Coupier, Boehringer-Ingelheim, France  
Chun Fang Shen, NRC, USA  
Amine Kamen, MacGill University, Canada  
Hervé Poulet, Boehringer-Ingelheim, France  
Noël Detraz, Boehringer-Ingelheim, France  
Zahia Hannas, Boehringer-Ingelheim, France

**Key Words:** Medium culture, baculovirus system, proprietary formula, medium supplier, animal origin free.

Insect cells & baculovirus expression vector system (BEVS) is an efficient platform for the production of baculovirus vectors and the expression of recombinant proteins or VLPs (Virus Like Particles). This technology is increasingly used in large-scale manufacturing of human and veterinary vaccines. The production of safe and cost-effective vaccines requires the development of animal origin free and low-cost culture media supporting strong insect cell growth, high yield of baculovirus and sustained expression of recombinant proteins or VLPs. In this context, Boehringer-Ingelheim decided to develop its own animal origin free media (with similar or better performance than the commercial one) in collaboration with NRC and suppliers. The different steps, feedback and results will be presented in this poster.